About: Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 27 May 2020

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) article scientifique publié en 2020 (fr) artículu científicu espublizáu en mayu de 2020 (ast) scientific article published on 27 May 2020 (en) наукова стаття, опублікована 27 травня 2020 (uk)
publication date	wds:Q95942677-DCC7B740-6DAE-4BB5-93B8-B228DFAD112B wds:Q95942677-F21B3301-7DBE-4E2F-97BB-883F33DCAF70
publication date	2020-05-27 00:00:00Z (xsd:dateTime) 2020-06-10 00:00:00Z (xsd:dateTime)
rdfs:label	Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19 (en) Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19 (nl)
skos:prefLabel	Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19 (en) Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19 (nl)
name	Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19 (en) Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19 (nl)
author	wds:Q95942677-0B710763-63F7-4D14-9ADD-42085530737F wds:Q95942677-7D9DCB3C-8035-4530-9BA1-B9118512B707
author	Akiko Iwasaki Annsea Park
title	wds:Q95942677-D371983C-C415-42E5-BCA4-AB66414D4733
title	Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19 (en)
instance of	wds:Q95942677-98B038A0-C330-4C35-960B-6E42DFFEB980 wds:Q95942677-9A0FBDF3-50A0-44EE-A732-CE032FF21331
instance of	review article scholarly article
main subject	wds:Q95942677-7152E65C-AABC-46BF-A7B1-BB352F3FD0ED
main subject	COVID-19 mortality
PubMed ID	wds:Q95942677-736A92A7-B65C-433B-BC31-7D3768F2F8C7
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/32464097
PubMed ID	32464097
published in	wds:Q95942677-CD28B310-9711-405A-AB14-7525B2F23953
published in	Cell Host & Microbe
DOI	wds:Q95942677-FA80CB3F-EBCF-4457-AACA-4B4C008542D7
DOI	http://dx.doi.org/10.1016/J.CHOM.2020.05.008
DOI	10.1016/J.CHOM.2020.05.008
PMCID	wds:Q95942677-6C16646C-AC1A-43E6-8834-1FBC79641D67
PMCID	7255347
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q95942677
is cites work of	SARS-CoV-2 activates/modulates innate and adaptive immune responses Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children Evaluation of the Xiamen AmonMed Biotechnology rapid diagnostic test COVID-19 IgM/IgG test kit (Colloidal gold) COVID-19 Disease Map, a computational knowledge repository of SARS-CoV-2 virus-host interaction mechanisms Antagonism of Type I Interferon by Severe Acute Respiratory Syndrome Coronavirus 2 SARS-CoV-2 Nonstructural Protein 1 Inhibits the Interferon Response by Causing Depletion of Key Host Signaling Factors SARS-CoV-2 membrane glycoprotein M antagonizes the MAVS-mediated innate antiviral response COVID19 Disease Map, a computational knowledge repository of virus–host interaction mechanisms IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant Characteristics of SARS-CoV-2 and COVID-19 Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions Evasion of Type I Interferon by SARS-CoV-2 Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and coronaviruses by depleting membrane cholesterol Syncytia formation by SARS-CoV-2 infected cells SARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety family member 2 Simeprevir potently suppresses SARS-CoV-2 replication and synergizes with remdesivir Simeprevir Potently Suppresses SARS-CoV-2 Replication and Synergizes with Remdesivir SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection The mechanisms of action of Ivermectin against SARS-CoV-2: An evidence-based clinical review article Host factors facilitating SARS-CoV-2 virus infection and replication in the lungs COVID-19: neonatal-perinatal perspectives SARS-CoV-2 nsp12 attenuates type I interferon production by inhibiting IRF3 nuclear translocation SARS-CoV-2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG-I/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING signaling pathways SARS-CoV-2 triggers an MDA-5-dependent interferon response which is unable to control replication in lung epithelial cells Mechanisms of Antiviral Immune Evasion of SARS-CoV-2 SARS-CoV-2 ORF9b inhibits RIG-I-MAVS antiviral signaling by interrupting K63-linked ubiquitination of NEMO An aberrant STAT pathway is central to COVID-19 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling SARS-CoV-2 infects blood monocytes to activate NLRP3 and AIM2 inflammasomes, pyroptosis and cytokine release Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic? SARS-CoV-2 ORF9b Antagonizes Type I and III Interferons by Targeting Multiple Components of RIG-I/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING Signaling Pathways The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19 Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Membrane (M) Protein Inhibits Type I and III Interferon Production by Targeting RIG-I/MDA-5 Signaling Dual Nature of Type I Interferons in SARS-CoV-2-Induced Inflammation The current landscape of coronavirus-host protein-protein interactions Verification of SARS-CoV-2-Encoded small RNAs and contribution to Infection-Associated lung inflammation SARS-CoV-2 spike protein–induced cell fusion activates the cGAS-STING pathway and the interferon response SARS-CoV-2 Nsp5 Demonstrates Two Distinct Mechanisms Targeting RIG-I and MAVS To Evade the Innate Immune Response Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Membrane (M) and Spike (S) Proteins Antagonize Host Type I Interferon Response The Many Faces of JAKs and STATs Within the COVID-19 Storm Integrate structural analysis, isoform diversity, and interferon-inductive propensity of ACE2 to predict SARS-CoV2 susceptibility in vertebrates Immunity, endothelial injury and complement-induced coagulopathy in COVID-19 Targeting CTP Synthetase 1 to Restore Interferon Induction and Impede Nucleotide Synthesis in SARS-CoV-2 Infection Effect of combination of interferon alpha-2b and interferon-gamma or interferon alpha-2b alone for elimination of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19 SARS-CoV-2 inhibits induction of the MHC class I pathway by targeting the STAT1-IRF1-NLRC5 axis A Bacterial Cell-Based Assay To Study SARS-CoV-2 Protein-Protein Interactions Type I and III IFN-mediated antiviral actions counteracted by SARS-CoV-2 proteins and host inherited factors SARS-CoV-2-Encoded MiRNAs Inhibit Host Type I Interferon Pathway and Mediate Allelic Differential Expression of Susceptible Gene Why Females Do Better: The X Chromosomal TLR7 Gene-Dose Effect in COVID-19 A-to-I RNA editing in SARS-COV-2: real or artifact?
is cites work of	wds:Q96432116-AFD2B80A-DF47-4334-9E42-C02E53FC23D9 wds:Q99730575-4F797CE6-338D-4EE1-9F41-9B75B074AE22 wds:Q100465248-DD60F1C6-E879-4994-A12C-409A593A21DE wds:Q109116651-8572E8A7-3E7E-422E-99DC-03B94A9849D8 wds:Q99561921-EDD81528-B89A-4CA5-B8F4-EC15E30B2B9E wds:Q104439722-29AB536E-CFAB-4140-ACA8-76580EF015E0

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software